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A B S T R A C T
In colorectal cancer patients, iron therapy, and especially intravenous iron therapy, is increasingly used to treat
anemia and reduce the use of blood transfusions. However, iron has also been shown to be an essential nutrient
for rapidly proliferating tissues and cells. In this respect, anemia of inﬂammation, characterized by limited
duodenal iron uptake and sequestration of iron into the reticuloendothelial system, might be regarded as a
potentially eﬀective defense strategy of the human body against tumor growth. We therefore hypothesize that
iron therapy, by supporting colorectal tumor growth and increasing the metastatic potential, may worsen tumor
prognosis in colorectal cancer patients. This hypothesis is particularly supported for colorectal cancer by la-
boratory, epidemiological and animal studies, demonstrating the role of iron in all aspects of tumor development
growth. Compared to non-malignant colon cells, tumor cells diﬀer in the levels and activity of many iron import
and export proteins, resulting in an increase in intracellular iron level and enhanced proliferation. In addition, it
is demonstrated that iron is able to amplify Wnt signaling in tumors with Apc mutation, a critical mutation in the
development of colorectal cancer. If our hypothesis is to be conﬁrmed, current practice of iron administration, as
treatment for anemia and as replacement of blood transfusions, can be hazardous and should be completely
reconsidered.
Introduction
Colorectal cancer is the third most commonly diagnosed cancer in
men and the second in women worldwide, accounting for more than 1.4
million new cases and 694 000 associated deaths worldwide [1]. An-
emia (hemoglobin<12.0 g/dL) is the most frequent hematological
manifestation in patients with cancer, occurring in> 40% of the cases.
In colorectal cancer, anemia is even reported in around 60% of the
cases [2]. This anemia is most often associated with iron deﬁciency [3],
but more importantly also with impaired disease-free and overall sur-
vival in cancer patients [4,5].
As both blood transfusions and erythropoiesis-stimulating agents
(ESAs) are, similar to anemia, independently associated with an in-
creased risk of colorectal cancer recurrence and increased mortality
[6–9], the use of iron to reverse anemia has gained more attention. In
this regard, while oral iron does correct anemia, it also causes
constipation, and is largely ineﬀective in patients with anemia of in-
ﬂammation, characterized by reduced duodenal iron uptake and iron
mobilization from the reticulo-endothelial system. In comparison with
oral iron, intravenous iron does not have these disadvantages and is
therefore more and more preferred [10]. In colorectal cancer patients,
several cohort studies have shown that intravenous iron therapy indeed
optimizes preoperative hemoglobin level. A net reduction of blood
transfusions by intravenous iron, however, is not conclusively shown as
of yet [11–14].
In contrast to the short-term eﬀect of iron therapy to increase the
hemoglobin level, strikingly, possible long-term eﬀects in colorectal
cancer patients, such as survival, are so far hardly studied. These long-
term eﬀects are of special interest since anemia of inﬂammation is
believed to be a potentially defense strategy of the human body to limit
the growth of tumor cells [15]. In this respect, the results of laboratory,
epidemiological and animal studies indeed have shown iron’s role in all
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aspects of cancer development and cancer growth [11,16–21]. Finally,
corroborating evidence implicates that especially gastrointestinal
cancer cells, likely by their original iron-absorbing nature, have an al-
tered iron homeostasis [22].
The hypothesis
We hypothesize that iron therapy may worsen colorectal tumor
prognosis by supporting colorectal tumor growth and increasing the
metastatic potential. Although no direct evidence is available to date,
accumulative data from experimental studies are in favor of this hy-
pothesis. In this respect, importantly, iron therapy is increasingly used
with the aim of optimizing hemoglobin level and reducing the need for
blood transfusions. Therefore, this hypothesis is in striking contrast
with current practice in patient blood management. We evaluated the
current evidence supporting this hypothesis in the following part.
Evaluation of the hypothesis
Iron is an essential nutrient participating in numerous biological
and cellular processes such as hemoglobin-mediated oxygen transport,
DNA synthesis and cell proliferation and growth. As mammals do not
possess any regulated mechanisms for iron excretion from the body,
iron metabolism is maintained by the tight control of dietary iron ab-
sorption in the duodenum. Intracellular iron transport is mainly con-
trolled by three iron transport proteins: 1. divalent metal transporter 1
(DMT1), facilitating the transport of dietary iron across the apical
membrane of enterocytes 2. ferroportin, facilitating the export across
the basolateral membrane into the bloodstream, and 3. transferrin re-
ceptor 1 (TfR1), facilitating the import across the basolateral membrane
into the cell. Systemically, iron homeostasis is regulated by hepcidin,
which is produced by hepatocytes and inhibits the release of iron from
enterocytes and macrophages into the circulation by inducing the in-
ternalization and subsequent degradation of ferroportin [23,24]. The
level of hepcidin is controlled by many factors including iron stores,
hypoxia, anemia and erythropoiesis [25,26]. Whereas iron deﬁciency,
enhanced red blood cell production, and hypoxia decrease hepcidin
expression to accelerate iron absorption, iron overload and in-
ﬂammatory stimuli like IL-6 induce increased hepcidin expression. The
latter is the cause of a hepcidin-mediated decrease in iron uptake and
utilization, so called anemia of chronic disease or anemia of in-
ﬂammation.
Abovementioned background information on the normal regulation
of iron metabolism is essential to put the modiﬁcations in intracellular
iron regulation in colorectal cancer cells in perspective. In distinct favor
of our hypothesis, many transport proteins that were originally studied
for their roles in normal iron metabolism have now been shown to
contribute to malignant tumor growth. Compared to non-malignant
colon cells, iron import proteins, such as DMT1 and TfR1, are upregu-
lated, while ferroportin, the only known iron export protein, is down-
regulated in colon tumor cells, subverting the normal homeostatic
control into a chronic iron acquisition state enabling enhanced pro-
liferation [27–29]. More in detail, the presence of the key intestinal
tumor suppressor Apc seems to play a pivotal role. The Apc gene is the
most commonly mutated tumor suppressor gene in sporadic colorectal
cancer [30], and it is shown that especially Apc-deﬁcient (i.e. mutant
Apc) cells appear critically dependent iron for eﬃcient tumor growth.
In Apc-deﬁcient cells, raising the levels of iron induces the expression of
TfR1 and DMT1, resulting in increased iron content in the cells and
increased proliferation, while removal of iron drives apoptosis of Apc-
deﬁcient cells. This is the exact opposite to what is observed in color-
ectal cancer cells with wildtype Apc [17,31]. In addition, it is demon-
strated that, in mouse models, the growth rate of tumor xenografts is
increased by high levels of dietary iron [32,33].
Finally, in studying the proliferative eﬀect of iron in colorectal tu-
mors, a clear link between iron and Wnt signaling was found
[30,34,35]. Wnt signaling plays a critical role in regulating homeostasis
and self-renewal of tissues, and in the intestinal epithelium it promotes
proliferation and diﬀerentiation of stem cells in the intestinal crypts.
Aberrant Wnt signaling is closely related to a mutation in Apc, and is an
important hallmark for colorectal cancer development. Importantly,
and supporting our hypothesis, it is demonstrated that iron, in the
background of an Apc mutation, is able to amplify Wnt signaling, and
with it induction of cell growth [36]. Therefore, in the presence of an
Apc mutation, iron will aﬀect Wnt signaling and with it an increase in
the tumorigenic and metastatic potential [37].
Consequences of the hypothesis and discussion
Substantial evidence suggests that iron promotes colorectal tumor
growth and potentially increases the metastatic potential of colorectal
tumor cells. Therefore, the legitimate question arises as to whether the
use of iron therapy, either orally or intravenously, is a safe and optimal
treatment strategy in anemic colorectal cancer patients.
We hypothesize that iron in general (i.e. both oral and intravenous)
may worsen colorectal tumor prognosis, but the diﬀerent routes of
administration should be considered. In colorectal cancer patients, oral
iron often is poorly absorbed. As a consequence, only a fraction of the
dietary (i.e. orally administered) iron will reach the sites of ery-
thropoiesis and a signiﬁcant part will reach the site of the primary
tumor. At the site of the primary tumor, the oral iron will be able to
aﬀect Wnt signaling and contribute to enhanced tumor growth and
increased metastatic potential. However, and in contrast with in-
travenous iron, the eﬀect of oral iron will be limited to the primary
tumor. In this respect, intravenous iron might have more inﬂuence if
metastases are present.
In addition to the diﬀerent routes of administration, we hypothesize
that the assessment of type of iron deﬁciency anemia might be im-
portant in studying the long-term eﬀect of iron therapy. Chronic blood
loss, as can be envisioned by bleeding from gastrointestinal tumors, in
this respect causes absolute iron deﬁciency (AID), characterized by
depleted iron stores. Functional iron deﬁciency (FID), in contrast, is
caused by impaired iron homeostasis and is, due to increased hepcidin
production, characterized by reduced iron uptake from the duodenum
and iron mobilization from the reticulo-endothelial system. FID re-
sulting in anemia is also known as anemia of inﬂammation or anemia of
chronic disease. Despite deﬁnite evidence, FID could be regarded as a
potentially eﬀective defense strategy to inhibit growth of pathogens and
tumor cells [15]. As, in the event of FID, a large fraction of oral iron
will, due to poor absorption in the duodenum, reach the site of the
primary tumor, we hypothesize that iron supplementation will be more
hazardous in patients with FID, as compared to patients with AID.
In assessing the eﬀect of iron therapy on tumor growth and tumor
prognosis, the dose-response relationship will be particularly im-
portant. A single dose of intravenous iron normally contains 1000mg,
which is, as compared to a daily iron uptake of 1–2mg, an extremely
high amount of extra iron. Total body iron is 3–4 g, and this quantity is
tightly regulated. However, the body has no mechanism to excrete
excess iron and only less than 0.1% of total iron is lost on average daily,
mostly through urine, sweat and feces. Therefore, and despite the re-
latively large amount of 3–4 g of total body iron, we hypothesize that a
single dose of intravenous iron or continuous supplementation of oral
iron (i.e. normally 400–500mg daily) could already aﬀect tumor
growth and therefore be harmful, especially in iron-dependent tumors.
Testing our hypothesis will be challenging. In a retrospective cohort
study signiﬁcant diﬀerences between an iron-treatment and non-iron
treatment group (e.g. baseline hemoglobin levels and use of blood
transfusions) could, despite possible correction by multivariable re-
gressions analyses, potentially indicate selection bias and have sig-
niﬁcant impact on the outcome. Therefore, to show the validity of our
hypothesis, the clinical long-term eﬀect of iron therapy should be stu-
died in a prospective trial. In such a trial, anemic patients should be
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randomized into an iron-treatment and a non-treatment group. In ad-
dition, clinical outcome should be correlated with both tumor (e.g.
expression levels of iron transporters, Apc status, tumor stage and
molecular subtype [38]) and patient characteristics. Only such a set up
will allow identiﬁcation of iron-dependent tumor growth and potential
high-risk patients. Apart from studying the clinical long-term con-
sequences of iron therapy, assessing the optimal management of anemia
in colorectal cancer patients is more challenging. For this purpose, the
detrimental long-term eﬀects of iron treatment must be compared with
those of not only anemia, but also alternatives to treat anemia like ESAs
and more important blood transfusions. The problem here is that a
head-to-head comparison of blood transfusion and iron therapy seems
almost impossible. The indications for both therapies are namely clearly
diﬀerent. Iron therapy is indicated in patients with a mild to moderate
anemia, while blood transfusion are only administered in case of severe
anemia. As a useful alternative for clinically assessing the optimal
management of anemia, animal experiments could be considered. In an
ortho- or heterotopic rodent model, the eﬀect on tumor growth of both
anemia, blood transfusion and iron therapy (both oral and intravenous)
could be accurately assessed and compared.
In conducting a prospective trial randomizing anemic patients in an
iron-treatment and a non-treatment group, ethical issues should be
considered. Anemia itself is considered as a major risk factor for im-
paired disease-free and overall survival in cancer patients [4,5], and
therefore the inclusion of a non-treatment (i.e. anemic) group could be
considered unethical. To challenge this ethical issue, the proposed and
abovementioned animal experiments studying the eﬀect on tumor
growth of both anemia, blood transfusion and iron therapy will play a
pivotal role. These animal experiments should precede a clinical trial
studying the long-term eﬀects of iron therapy. If anemia is proven to be
signiﬁcantly associated with highest tumor growth, the clinical study
design should be reconsidered. This could, for example, include the
administration of iron therapy in all anemic patients, subdivided into
patients with iron-dependent and non-iron dependent colorectal tumor
phenotypes. Assessment of the iron-dependency of the tumor could be
done by identiﬁcation of gene and protein expression levels of iron
transporters. If iron therapy is proven to be signiﬁcantly associated with
impaired tumor prognosis in the iron-dependent group, this probably
indicates the hazardous eﬀect of iron therapy.
Interestingly, corroborating data about the possible detrimental ef-
fects of iron can be deduced from a report by Harlaar et al. [39] com-
paring the long-term eﬀects of autologous and allogeneic blood trans-
fusions in colorectal cancer patients. They unexpectedly showed that
patients with autologous blood transfusion, with an a priori lower
probability to dysregulate the immune system of the recipient, showed
an inferior long-term survival as compared to patients transfused with
allogeneic blood. Interestingly, the patients with autologous blood
transfusion additionally received preoperative oral iron therapy to
maintain normal hemoglobin levels after blood donation.
In conclusion, if iron therapy indeed can be shown to worsen col-
orectal tumor prognosis, this should change current management of
anemia in colorectal cancer patients. Focus will be shifted, and mini-
mization of the use of blood transfusions will no longer be the main
objective. Paradigms will be shifted in patient blood management,
which will bear major changes in oncological care as a whole.
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